

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (Managed access partial review of TA663)

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No.	

2.	What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
Not relevant.	

3.	Has any change to the draft scope been agreed to highlight potential equality issues?
Not relevant.	

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
----	---

Not relevant.

Approved by Associate Director (name): Ross Dent

Date: 07/05/2025